Latest News

• February 2020
  Oncostellae received regulatory approval to start a proof of concept study with OST-122 in patients with ulcerative colitis
  
  
• May 2019
  OST-122 has successfully completed a Phase 1b trial in HV and has proved to be GI-restricted and well tolerated up to 1200 mg after multiple dosing
• 23-25 Mar 2020
  Oncostellae participates at the BIO-Europe partnering conference in Paris